-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The Guangdong Super League is expected to set off a new round of drug price reduction frenzy
The purchased varieties involved this time are not unfamiliar to the industry.
Separately set up two types of procurement product lists, up to 6 shortlisted
Judging from the specific rules and details, the procurement plan announced by the Guangdong Super League this time is remarkable
① If there is only one over-evaluated B purchase order that meets the qualifications for registration, the same product serial number and the same medical insurance dosage form, it will be included in the over-evaluated A purchase order and no over-evaluated B purchase order
② If different generic drugs are jointly bid, the generic drugs, original research drugs and reference preparations that have passed the consistency evaluation will be included in the over-rated A purchase order
③If the dosage form with the same generic name is exclusive, in principle, the purchase order can be combined according to the same route of administration or the dosage form with a price difference relationship
Since the list of purchased products distinguishes between over-evaluated and non-over-evaluated types, in the reporting of medical institutions, Guangdong proposes that public medical institutions should fill in the next year’s pre-purchased volume corresponding to the approval number, dosage form, and specifications of the over-evaluated drugs.
Although the specific proportion of the above groupings has not yet been determined, combined with the selection rules, it will obviously benefit the dominant enterprises in the original market
The B purchase order is based on whether the product is over-evaluated or not.
A purchase order product declares the step price and obtains the amount to be allocated
It is worth mentioning that the procurement plan requires that the declaring company shall reasonably declare the step price of the A purchase order product in accordance with the principle of quantity-price linkage
The level of the tiered quotation will determine the preferred choice of the selected pharmaceutical companies for the additional amount to be allocated
In addition, the procurement plan puts forward requirements on the selected enterprises and medical institutions for the increase in use outside the agreement
Super alliance speeds up the pace of inter-provincial procurement
Under the requirements of the normalized and institutionalized development of centralized drug procurement, the drug procurement initiated by provincial and local alliances has blossomed across the country, while Guangdong, which is the largest in the domestic pharmaceutical market, is Shanshan.
In April this year, the Guangdong Provincial Medical Insurance Bureau issued the "Implementation Plan on Promoting the Normalization and Institutionalization of Drug Group Procurement Work (Draft for Comment)", which officially announced the province's drug centralized procurement plan
From the perspective of the industry, the centralized procurement of the cephalexin alliance led by Guangdong is not just a simple contract renewal.
However, it is still unknown whether the other 16 provinces in the Guangdong Super League will follow the bids in each batch.
Judging from the list of reports from Jiangxi, Gansu and other provinces, the number of varieties is not the same.
Each province follows the bids according to local conditions.
Or a high probability event
.
However, it cannot be denied that the birth of the Guangdong Super League will fully accelerate the pace of inter-provincial volume procurement, and the unification of the national pharmaceutical market's product regulations and prices is expected to be accelerated
.